Publications by authors named "Ryudai Abe"
Article Synopsis
- Adenocarcinoma with ROS1 rearrangement is uncommon, and when it leads to carcinomatous pericarditis, it usually indicates advanced disease that poses significant health risks.
- A 21-year-old male experienced severe breathing difficulties due to cardiac tamponade, which was later confirmed through echocardiography and linked to ROS1-rearranged lung cancer identified from his pericardial fluid.
- The treatment with entrectinib was highly successful, significantly reducing his tumor marker levels and effectively managing his cardiac symptoms.
Background: Treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has a higher response rate than with conventional chemotherapy in patients positive for EGFR mutations. However, the efficacy of EGFR-TKI therapy may be reduced in patients positive for the EGFR exon 21 L858R point mutation.
Objective: To determine the clinical characteristics of patients with EGFR exon 21 L858R point mutation-positive NSCLC who are non-responders to EGFR-TKI therapy and the factors that predict response to EGFR-TKI therapy.
Background: Pemetrexed (PEM) is the primary chemotherapy for non-small cell lung cancer (NSCLC), showing potential for long-term disease stability in certain cases. However, studies examining disease control with PEM therapy are lacking. This study aimed to pinpoint clinical traits in patients with NSCLC responding well to PEM therapy, predict factors influencing disease control, and suggest optimal treatment approaches.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of docetaxel (DTX) and DTX plus ramucirumab (RAM) as second-line treatments for advanced non-small cell lung cancer (NSCLC), aiming to identify which patients are more likely to respond to these therapies.
- Out of 53 analyzed patients, only 22.6% showed a positive response to the treatments, with significant factors predicting nonresponse being lack of prior immune checkpoint inhibitors and reduction in DTX dosage after the second cycle.
- The findings indicate that maintaining DTX dosage and avoiding treatment with immune checkpoint inhibitors before administering DTX or DTX + RAM could improve response rates and overall survival in NSCLC patients.
Background: Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non-small cell lung cancer (NSCLC) patients with programmed death ligand-1 (PD-L1) expression ≥50%. However, the efficacy of ICI monotherapy in patients with PD-L1 expression <50% has not yet been fully elucidated. The aim of this study was to identify the clinical characteristics of NSCLC patients with PD-L1 expression <50% who respond to single-agent ICIs and factors that predict response.
View Article and Find Full Text PDF